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Laser capture microdissection and two-dimensional difference gel electrophoresis were used to 
establish the proteomic profiles for tumor and matched adjacent tissues from 12 patients. Differential 
protein spots were identified by mass spectrometric analysis. The cDNA of the differential protein was 
transfected into colorectal cancer cells, and the biological behavior of these cells was observed. The 
proteomic profile in colorectal cancer tissues was significantly different from that in normal adjacent 
tissues. There was a 1.5-fold difference and 60 differential protein spots between cancer and adjacent 
tissues. Ten differential protein spots were analyzed. Among them, two protein spots were 
down-regulated and eight protein spots were up-regulated in the primary tumor tissues. After 
identification by mass spectrometry, the two down-regulated proteins were carbonic anhydrase II and 
protein disulfide isomerase, and these eight up-regulated proteins included APC-stimulated guanine 
nucleotide exchange factor, phosphoglycerate kinase 1, fumarate hydratase, aldolase A, activator 
protein 2B, glutathione S-transferase A3, Arginase and zinc finger protein 64 homolog. After been 
transfected with carbonic anhydrase II, the invasive ability, mobility and drug resistance of colon cancer 
lovo cells were significantly reduced. The proteomic profile was significantly different between 
colorectal cancer tissues and normal adjacent tissues. The down-regulation of carbonic anhydrase II 
and protein disulfide isomerase and up-regulation of APC-stimulated guanine nucleotide exchange facto, 
aldolase A, glutathione S-transferase A3 and arginase were correlated with the onset of colorectal 
cancer.  
 





Colorectal cancer (CRC) is one of the common malignant 
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phosphate-buffered saline. 
mortality ranks the second among all cancers (Jemal et al., 
2008; Ferlay et al., 2007). The development and progres- 
sion of CRC is a multistep procedure with distinct genetic 
events occurring at different stages (Fearon and 
Vogelstein, 1990). This process may require 15 to 20 
years, with the transition from adenoma to adeno- 
carcinoma taking up to 10 years (Morson, 1974). Early 
diagnosis is the key point for the treatment and prevention 
of malignant tumors. However, there is no special 
symptom in the early stage of malignant tumors. The 
majority of the malignant tumors were in the advanced 
stage when they were diagnosed, with extensive 
metastases. Therefore, new suitable tumor markers were 
especially important for the early diagnosis and treatment 
of malignant tumors (Chignard and Beretta, 2004). 





diagnosis of CRC. However, it is very difficult to be 
accepted by patients without symptoms or with slight 
symptoms due to its invasion. The known tumor markers 
such as CEA and CA199 are not suitable for the 
screening and early diagnosis of CRC due to their low 
sensitivity and specificity. Therefore, currently, tumor 
markers with high sensitivity and specificity were deficient 
for the early diagnosis of CRC clinically.     
As a technique with high-flux and high resolution, pro- 
teomics has been widely applied in proteome analysis of 
tumors (Cho, 2007a). The onset and development of the 
tissues and cells can be detected at the entire protein 
level through analyzing the differential expression of 
proteins. The combination of 2-DE and mass spectro- 
metry can be used to identify differential proteins between 
tumor cells and normal original cells, and these differential 
proteins imply a large quantity of biological information. 
Some of the special proteins are special markers of 
tumors (Kim and Kim, 2007). The most consistently 
successful proteomic method is the combination of 
two-dimensional gel electrophoresis (2DE) for protein 
separation and visualization and mass spectrometric (MS) 
identification of proteins using peptide mass fingerprints 
and tandem MS peptide sequencing. Laser capture 
microdissection (LCM) is used to precisely harvest tumor 
tissues from the sample, avoiding the interference of other 
tissues. Therefore, it can better reflect the change of the 
proteins in the tumor tissues (Ornstein et al., 2000; Simone 
et al., 2000). Two-dimensional differential in-gel 
electrophoresis (2D DIGE) is a kind of method to precisely 
analyze the differential protein abundance of the samples, 
in which the protein sample was labeled before 2-D 
electrophoresis. The 2-D DIGE methodology was initially 
described by Unlu et al (1997). In this method, the 
compared protein samples are labeled with different 
fluorescent dyes and then analyzed together in the same 
2-D electrophoresis gel. It is possible to separate up to 
three different labeled samples within the same 2D gel. 
The comparison between normal and cancer tissues is a 
common proteomic approach, with obvious benefits for 
the identification of differentially expressed markers. In an 
early study, paired patient samples from normal and 
neoplastic tissues were used for characterization of 
differences in protein profiles during CRC progression. 
Cancer tissues were staged according to Duke’s 
classification. A significant alteration of 18 proteins was 
identified by quantitative studies during tumor formation 
(Stulik et al., 2001). More proteins that appear to change 
consistently among patients with CRC were identified 
through several other comparative proteomic studies of 
human colorectal cancers and adjacent normal tissue 
identified (Friedman et al., 2004; Alfonso et al., 2005; Kim 
et al., 2009).  
In our study, the differential proteins between colorectal 
cancer tissues and normal adjacent tissues were 
analyzed by using LCM, 2D DIGE and liquid 
chromatography tandem mass spectrometry, and the 
CRC-related proteins were separated and identified.  




Effects of these proteins on the biological behavior of 
colorectal cancer cells were explored. This approach may 
help to identify proteins that could be useful as new tool in 
the diagnosis or prognosis of this type of patients and 
perhaps to develop new therapeutic strategies to better 
aid therapy on the neoplastic target while minimizing the 
impact on normal tissues.   
 
 




Tissue samples were obtained from patients (6 men and 6 women; 
median age: 53 years; age range: 38 -71 years) who had undergone 
surgical resection for primary sporadic colorectal adenocarcinomas 
at the Department of General Surgery, General Hospital of Beijing 
Military Command, Beijing, China. None of the patients received any 
drug therapy for at least 3 months before surgery. All patients were 
thoroughly informed about the study and gave written consent for 
the investigation in accordance with the ethical guidelines of the 
Local Ethical Committee.   
Matched sets of colorectal cancer and normal colon mucosa (10 
cm from the edge of tumorous lesions) used for 2-D DIGE analyses 
were obtained within 30 min after surgical resection. The tissue 
samples were checked and sliced by a pathologist. All samples were 
diagnosed by histopathology as colorectal cancer.  
Samples of small colorectal cancers were collected from the distal 
colon and rectum and were staged according to American Joint 
Committee on Cancer classification. Six tumors were located in the 
distal colon, and six tumors were located in the rectum. All twelve 
tumors were adenocarcinoma classified as moderately differentiated. 
Every tumor was at stage I (T1-2, N0 and M0). Cancer tissue (from 
the edge of the tumor) and adjacent normal mucosa (at least 10 cm 





DTT, urea, thiourea, CHAPS, SDS, IPG buffer, pharmalyte, IPG gel 
strip (18 cm, 3 – 10 NL), acrylamide, N, N-methylenebis-acrylamide 
and PMSF were purchased from Amersham Pharmacia Biotech 
(Uppsala, Sweden). 2-D gels were cast and run in a Bio-Rad Multi 
Cell. CyDye DIGE was purchased from GE Healthcare (USA). 
HPLC- grade ACN, formic acid and TFA were purchased from 
Sigma (St Louis, USA). All buffers were prepared with Milli-Q water 
(Millipore, Bedford, USA).  
 
 
LCM/2D-DIGE analysis  
 
2-D DIGE was carried out according to the instructions of Ettan 
DIGE which was provided by GE Healthcare. Tumor and 
patient-matched normal colon mucosa from 12 patients were 
stained with nuclear fast red and subjected to LCM using an 
Arcturus PixCell IIe microscope (Arcturus, Conifer, CO). Protein 
from captured cells was extracted and quantified. The 12 patients 
were then randomly divided into four groups, with 3 patients in each 
group. 2-D DIGE was carried out according to Table 1. An internal 
standard pool generated by combining equal amounts of extracts 
from all 3 pairs of tumor and normal mucosa tissues (totally 6 
samples) was labeled with Cy2 fluorescent dye. It is able to 
minimize gel-to-gel variation by allowing the inclusion of an internal 
standard within each gel. All six samples evenly distributed between 
CyDye DIGE fluorescence Cy3 and Cy5 to minimize the variation 
between fluorescence. Fifty micrograms of each tumor and paired 
normal mucosa protein extracts were minimally labeled with Cy3 or 




Table 1. Experiment design of different fluorescent dye 
labeling for internal standard (Cy2) and sample 1, 2 and 3 
(Cy3 or Cy5). 
 
Gel 
Different fluorescent dye labeling 
Cy2 Cy3 Cy5 
1 Internal standard Normal 1 Cancer 2 
2 Internal standard Cancer 1 Normal 3 




Cy5 fluorescent dyes (400 pmol fluorescence/ 50 µg of protein  
extracts).  Labeling  reaction  wasperformed at 4°C for 30 min 
and quenched with 10 µl of lysine for 10 min on ice in dark. Equal 
amounts (50 µg) of quenched Cy3 or Cy5 labeled samples from 
each patient, together with the aliquoted 50 µg of Cy2-labeled 
internal standard pool (described above), were focused using IPG 
strips (Ready Strip, Bio-Rad, pH 3-10,18 cm) in the protein IEF Cell 
(Bio-Rad), with the addition of DeStreak Reagent (GE Healthcare). 
The IPG strips were equilibrated with equilibration buffers containing 
2% DTT and 2.5% iodoacetamide for 10 min each sequentially. For 
the first electrophoresis, an electric potential of 50 V was applied for 
12 h, 200 V for 1 h, 500 V for 1 h, 1000 V for 1 h, 10000 V for 1 h 
and 1000 V for 4 h. The second 12% SDS-PAGE was then carried 
out for all 3 gels simultaneously using Ettan DALT electrophoresis 
system (Bio-Rad). After electrophoresis, the gel was placed on 
light-resistant container with SDS electro- phoresis buffer at room 
temperature, and the gel was scanned immediately.  
 
 
DIGE image analysis 
 
Labeled proteins in each gel were visualized using a Typhoon 
9410™ (GE Healthcare) fluorescence scanner at 488/600 nm for 
Cy2, 532/580 nm for Cy3 and 633/520 nm for Cy5 dyes. Images 
were analyzed with the DeCyder™ software platform v 6.5 (GE 
Healthcare, USA). Gel image pairs were processed by the 
DeCyder™-DIA (Differential In-gel Analysis) software module to 
co-detect and differentially quantify the protein spots in the images, 
taking the sample as a reference to normalize the data, so the rest 
of the normalized spot maps could be compared among them. At the 
second stage, the DeCyder™-BVA (Biological Variation Analysis) 
software module was applied. BVA performs a gel-to-gel matching 
of the internal standard spot maps from each gel. Comparison 
between the different experimental groups and the control group 
was tested by student's t-test.  
 
 
Mass spectrometry analysis and database searching  
 
A replicate gel was made with 1 mg samples, and stained by 
Coomassie Brilliant Blue and then matched with the DIGE gel maps. 
The matched proteins spots were excised from gels and cleaved 
with trypsin by in-gel digestion. The peptides were subjected to 
liquid chromatography-tandem mass spectroscopy (LC-MS/MS) 
using an LTQ ion trap mass spectrometer (Thermo Scientific, 
Waltham, MA). Protein identities were determined from LC-MS/MS 
data using the sequest algorithm as implemented by the BioWorks 
Browser v 3.2 (Thermo Scientific) and searching against the 
National Center for Biotechnology Information (NCBI) database.  
 
 
Cell transfection  
 
The expression vector pcDNA3.1- carbonic anhydrase II was 





adenocarcinoma Lovo cells with the lipidosome transfection method. 
 
 
Biological behavior observation  
 
Cell invasion analysis 
 
Cell invasion basement membrane experiment was carried out in 
Transwell chambers (Costar Corporation). The number of cells in 
the field of vision was calculated. The invasive ability of cancer cells 
was expressed with the relative cell number of the invasive cells.  
 
 
Cell mobility analysis 
 
After polyester acid filter membrane (8 µm in pore size) was 
adhesive to the Transwell chamber, 5 µg of Fibronectin (Promega) 
was spread on the up- and down-surfaces of the filter membrane. 
After being digested with EDTA/PBS, about 2.5×10
5
 cells were 
added into the Transwell chamber. The number of cells in the field of 
vision was calculated. The mobility of cancer cells was expressed 





Cells with and without pcDNA3.1-carbonic anhydrase II transfection 
served as the experimental group and the control group. The 
inhibition ratio of 5-Fu and Oxaliplatin on cells were observed. 
Inhibition ratio = [1-(OD value of the experimental group/ OD value 
of the control group)] × 100%.  
 
 
Statistical analyses  
 
All data were analyzed with SPSS 12.0 software and the protein 
expression of different tissues was compared with t test. A p value of 







Tissues from 12 colorectal cancer patients were analyzed 
by 2-D DIGE. The spots were clearly distinguished, with 
about 1200 spots in each gel. The protein profile was 
significantly different between the colorectal cancer tissues 
and normal adjacent tissues. The DIGE image was analy- 
zed with DeCyder™ software to detect the differential spots 
(Figure 1). After background elimination, gel normalization 
and artifacts removal, the matching rate of each gel to the 
MASTER gel was more than 90%. There were 1.5-folds 
differential expression and 60 differential protein spots 
between tumor tissues and normal adjacent tissues. The 
differential spots were seen in Figures 2 and 3. It was found 
that there were two differential spots with 25-60 kD and 
pH 6.0 - 8.0 and eight differential spots with 25-80 kD, pH 
6.0 - 10.0. These spots stably appeared on the parallel gel. 




Mass spectrum analysis  
 
Eight differential protein spots with 5-folds different expression 






Figure 1. The scan result of one gel and the overlay map. Each gel contained the same pooled internal standard 
sample minimal dye labeled with CyDye DIGE Fluor Cy2 and two protein samples labeled with fluor Cy3 or Cy5 
minimal dyes. (A) Internal standard Cy2 dye. (B) Normal mucosa tissues Cy3 dye. (C) Cancer tissues Cy5 dye. 




were analyzed and identified with the LC- MS/MS method. 
Two differential spots with 25 - 60 kD and pH 6.0 - 8.0 
were up-regulated in normal adjacent tissues as 
compared with the tumor tissues. The result of mass 
spectrum showed that these two proteins were Carbonic 
Anhydrase II and protein disulfide isomerase (PDI). Eight 
differential spots with 25 - 80 kD and pH 6.0 - 10.0 were 
up-regulated in tumor tissues as compared with the 
normal adjacent tissues. They were APC-stimulated 
guanine nucleotide exchange factor, phosphoglycerate 
kinase 1, fumarate hydratase, aldolase A, activator protein 
2B, glutathione S-transferase A3, arginase and zinc finger 
protein 64 homolog (Table 2).  
 
 
Effects of carbonic anhydrase II cDNA transfection on 
the biological behavior of cells  
 
The pcDNA3.1- carbonic anhydrase II was successfully 
constructed and transfected into lovo cells. The invasion 
ability and mobility of carbonic anhydrase II-transfected 
cells were significantly decreased as compared with the 
non-transfected cells. The inhibition ratio of 5-Fu and 
oxaliplatin was significantly increased in the carbonic 
anhydrase II-transfected cells as compared with the 





The differential analysis of the protein profiles between 
tumor tissue and normal tissue is the most extensive and 
effective method in tumor proteomics (Lawrie et al., 2001; 
Simpson and Dorow, 2001). The combination of 2-D DIGE 
and MS is an effective method for screening the 
differential proteins of colorectal cancer. DIGE ensures 
the sensitivity and accuracy of protein detection, which is 
suitable for the analysis of differential protein profiles. The 
newly deve- loped quantitative proteomics has high 
sensitivity, dynamic range and reproducibility vs the 
conventional 2-D DIGE (Ong and Mann, 2005; Unlü et al., 
1997). Proteomic, together with other global technologies, 
have taken CRC research to a new era, providing a 
wealth of new informa- tion, sometimes at a pace too fast 
for proper validation and evaluation. Basic research 
relating to the understanding of the mechanisms of cancer











development has particularly benefited from these new 
approaches. But the promise of rapid development of 
novel clinical applications has not materialized yet. There 
is no doubt that there is room for improvement in all 
aspects of proteomic research (Georgia et al., 2009).  
As a difference with the previous studies, we used the 
approach of protein separation by 2D DIGE coupled with 
protein identification by LC-MS/MS analysis and database 
search. This analysis identified strongly discriminated 2 
down-regulated proteins and 8 up-regulated protein spots 
in colorectal cancer tissues. The identified proteins may 
be involved in the process of tumorigenesis and invasion. 
There were 2 unique proteins including CAII and PDI 
that were down-regulated in CRC tissues versus normal 
colon mucosa, which might be related to the onset and 
development of colorectal cancer. CAII is the key enzyme 
for adjusting acid-base homeostasis in human bodies. 
Our study showed that CAII could decrease the invasive 
ability and mobility of tumor. The low expression of CAII 
could promote the proliferation and metastasis of cancer 
cells. Therefore, CAII could be used for screening colon 
cancer, and could also be used for the prevention and 
treatment of the recurrence and metastasis of colorectal 
cancer (Okoyama et al., 1997). PDI which is located in 
endocyto-plasmic reticulum is an important protein fold 
catalyzer. It catalyzes the formation of protein disulfide 
linkage and the rearrangement of mispairing disulfide 
linkage, and also has molecular chaperones activity for 
inhibiting the aggregation of misfolding proteins. Disulfide 
bond formation is probably involved in the biogenesis of 
approximately one third of human proteins. A central player 
in this essential process is protein disulfide isomerase 
(PDI). PDI was the first protein-folding catalyst reported 
(Hatahet et al., 2009). The abnormal expression of PDI 
was also found in the CRC caco-2 cells (Stierum et al., 
2003). The restricted protein synthesis due to the low PDI 
expression may be correlated with the onset and 
development of colorectal cancer, the mechanism of which 
still requires further studies.  
There were eight unique proteins that were 
up-regulated in CRC tissues versus normal colon mucosa. 
APC- stimulated guanine nucleotide exchange factor acts 
as the guanine nucleotide exchange factor (GEF) for 
RhoA and RAC1 GTPases. Binding of APC may activate 
RAC1 GEF activity. The APC-ARHGEF4 complex seems to 
be involved in cell migration as well  as  in  E-cadherin- 















































Figure 3. Analysis of protein disulfide isomerase with DeCyder software (Left: tumor tissue; Right: 




mediated cell-cell adhesion (Sjöblom et al., 2006). 
Mutation of the tumor suppressor is a key early evented in 
the development of most colorectal tumors. APC pro- 
motes degradation of betacatenin and thereby negatively 
regulates Wnt signaling, whereas mutated APCs present 
in colorectal tumor cells are defective in this activity. APC 
also stimulates the activity of the guanine nucleotide 
exchange factor Asef and regulates cell morphology and 
migration. Truncated mutant APCs constitutively activate 
Asef and induce aberrant migration of colorectal tumor 
cells. Asef plays a critical role in tumor angiogenesis and 
may be a promising target for cancer chemotherapy 
(Kawasaki et al., 2010).  
Aldolase A expression was significantly and stably 
up-regulated in each sample. Aldolase plays an important 
role in glucose metabolism. Aldolase has a molecular weight 
of 160 kDa and has three isozymes, namely: aldolase A, 
B and C. The enzyme is probably present in all cells; it 
occurs in particularly large quantities in the muscles, liver 
and brain. Aldolase becomes elevated in serum with 
malignant tumors, and isozyme A is predominant in serum 
(Cho, 2007b), which has been confirmed by Western-blot 
and immunohistochemistry (Tomonaga et al., 2004). 
Aldolase A could serve as a biomarker for the diagnosis of 
colorectal cancer. However, its sensitivity and specificity 
need further studies. 
Some proteins such as glutathione S-transferase A3 
(GST A3) may be related to drug resistance of tumor cells. 
GST can promote drug metabolism and reduce the cyto- 
toxic effect of anti-tumor drug through  binding  lipophilic  
















1 29070 6.94 GI:4557395 carbonic anhydrase II [Homo sapiens] T < N 
2 57043 6.10 GI:860986 protein disulfide isomerase [Homo sapiens] T < N 
3 44615.4 8.30 GI：4505763 phosphoglycerate kinase 1 [Homo sapiens] T > N 
4 50385.6 7.23 GI:13111881 Fumarate hydratase [Homo sapiens] T > N 
5 39289 8.39 GI:28614 Aldolase A [Homo sapiens] T > N 
6 40874 9.33 GI:178705 activator protein 2B [Homo sapiens] T > N 
7 76159 6.69 GI:52782759 APC-stimulated guanine nucleotide exchange factor (Asef) T > N 
8 25302.5 9.21 GI:10443247 glutathione S-transferase A3 [Homo sapiens] T > N 
9 25357 8.67 GI:1197498 Arginase[Homo sapiens] T > N 
10 25933 8.19 GI:123233576 zinc finger protein 64 homolog (mouse) [Homo sapiens] T > N 
 
a 
Theoretical molecular weight of the matching protein in kDa; 
b
 Theoretical isoelectric point of the matching protein; 
c
 T, tumorous tissue; N, 




cytotoxic drug and increasing its water-solubility. GSTA3 
is also a high-performance catalytic isomerase during the 
biosynthesis of steroid hormone (Johansson and Mannervik, 
2001), the mechanism of which still needs further study.  
Some proteins may be related to the metastasis of 
colorectal cancer. Arginase is a kind of hydrolase in liver, 
which plays a catalytic effect in the final process of 
ornithine cycle and forms urea and ornithine eventually. 
Porembska et al. (2002) considered that the CRC patients 
with high serum arginase activity had high recurrence and 
metastasis. In our study, human arginase was 
significantly up-regulated in the colorectal cancer tissues. 
Human arginase may become a prognostic marker for the 
recurrence and metastasis of CRC. 
In summary, in the present study, we obtained some 
differential proteins through analyzing the proteome of 
colorectal cancer. These proteins may play a certain role 
in the tumorigenesis and metastasis. Some proteins may 
serve as the early prognostic biomarkers for colorectal 
cancer, which still needs large-sample studies. With the 
development of colorectal cancer proteomics, more 
significant differential proteins will be found and the 
mechanism of CRC will be further illuminated, and new 
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